Olmesartan Medoxomilo Generis (Olmesartan Medoxomil)

Olmesartan medoxil is an angiotensin II receptor blocker used to manage conditions related to the renin‑angiotensin system.

• Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk.
• Heart failure: improves symptoms and decreases hospitalisation rates when added to standard therapy.
• Diabetic nephropathy: slows progression of kidney disease by reducing intraglomerular pressure.

• Olmesartan medoxil is a prodrug that is rapidly converted to olmesartan, which selectively blocks the binding of angiotensin II to the AT1 receptor on vascular smooth muscle and adrenal tissue. This inhibition prevents vasoconstriction, aldosterone secretion, and sympathetic activation, leading to reduced peripheral resistance, lower blood pressure, and decreased cardiac workload.

Adverse reactions may occur with olmesartan therapy. Commonly reported events are generally mild and transient.

Common Side Effects

• Dizziness: sensation of light‑headedness, especially after dose initiation.
• Headache: mild to moderate intensity.
• Fatigue: feeling of tiredness without exertion.
• Upper respiratory tract infection: nasopharyngitis or mild cough.
• Diarrhoea: loose stools occurring intermittently.

Serious or Rare Side Effects

• Angioedema: swelling of face, lips, tongue, or airway requiring emergency care.
• Hyperkalaemia: elevated serum potassium that may cause cardiac arrhythmia.
• Acute renal failure: sudden decline in kidney function, especially in patients with pre‑existing renal disease.
• Severe hypotension: marked drop in blood pressure leading to dizziness or syncope.
• Hepatic injury: abnormal liver enzymes indicating possible liver damage.

Before initiating therapy, clinicians should consider several safety measures.

• Blood pressure monitoring: assess response and adjust dose to avoid hypotension.
• Renal function assessment: evaluate serum creatinine and eGFR periodically.
• Serum potassium check: monitor for hyperkalaemia, especially when combined with potassium‑sparing agents.
• Pregnancy contraindication: avoid use in pregnant women due to risk of fetal toxicity.
• Elderly caution: start at lower dose and titrate slowly.
• Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Concomitant use with aliskiren in diabetic patients: increased risk of renal impairment and hyperkalaemia.
• Dual blockade with ACE inhibitors or other ARBs: may cause excessive hypotension and kidney injury.
• Potassium‑sparing diuretics (e.g., spironolactone): heightened risk of hyperkalaemia.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function.
• Lithium: olmesartan can increase lithium levels, necessitating serum monitoring.
• Diuretics (thiazides): may enhance antihypertensive effect, requiring blood pressure checks.